Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR4A2 | P43354 | 2/20 | 0.57 |
| ▸ | MRGPRX4 | Q96LA9 | 4/20 | 0.54 |
| ▸ | LMNA | P02545 | 2/20 | 0.53 |
| ▸ | SGMS2 | Q8NHU3 | 1/20 | 0.51 |
| ▸ | MAOB | P27338 | 5/20 | 0.49 |
| ▸ | FOLH1 | Q04609 | 2/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.49 |
| ▸ | MAOA | P21397 | 1/20 | 0.49 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.49 |
| ▸ | RXRA | P19793 | 1/20 | 0.48 |
| ▸ | RXRB | P28702 | 1/20 | 0.48 |
| ▸ | RXRG | P48443 | 1/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | PTGER1 | P34995 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2453382 | 0.89 | LMNA (0.62) | NR4A2MRGPRX4LMNASGMS2MAOB | |
| SCHEMBL1097783 | 0.86 | MRGPRX4 (0.53) | NR4A2MRGPRX4LMNASGMS2MAOB | |
| SCHEMBL1097870 | 0.85 | FOLH1 (0.62) | SGMS2FOLH1L3MBTL1MEN1KMT2A | |
| SCHEMBL1097268 | 0.83 | MRGPRX4 (0.53) | MRGPRX4MAOBFOLH1RXRAPTGER1 | |
| SCHEMBL1097135 | 0.83 | MAOB (0.62) | MRGPRX4MAOBFOLH1MAOAPARP10 | |
| SCHEMBL1096673 | 0.83 | RXRA (0.57) | NR4A2MRGPRX4SGMS2MAOBRXRA | |
| SCHEMBL1097263 | 0.81 | MRGPRX4 (0.56) | MRGPRX4MAOBPTGER1 | |
| SCHEMBL1097781 | 0.80 | MRGPRX4 (0.55) | NR4A2MRGPRX4LMNASGMS2MAOB | |
| SCHEMBL1647303 | 0.80 | LRRK2 (0.67) | NR4A2MRGPRX4MAOBFOLH1 | |
| SCHEMBL1096347 | 0.79 | PTGER1 (0.49) | MRGPRX4FOLH1RXRARXRBRXRG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10385037-B2 | 4′-O-substituted isoindoline derivatives and compositions comprising and methods of using the same | CELGENE CORPORATION (US) | 2019-08-20 | — | — | US | disclosed |
| EP-3101017-B1 | 4'-O-SUBSTITUTED ISOINDOLINE DERIVATIVES AND COMPOSITIONS COMPRISING AND METHODS OF USING THE SAME | CELGENE CORP (US) | 2019-06-12 | — | — | EP | disclosed |
| US-20180155316-A1 | 4'-O-SUBSTITUTED ISOINDOLINE DERIVATIVES AND COMPOSITIONS COMPRISING AND METHODS OF USING THE SAME | CELGENE CORPORATION | 2018-06-07 | — | — | US | disclosed |
| US-9920027-B2 | 4′-O-substituted isoindoline derivatives and compositions comprising and methods of using the same | CELGENE CORPORATION (US) | 2018-03-20 | — | — | US | disclosed |
| US-RE46639-E1 | 4′-O-substituted isoindoline derivatives and compositions comprising and methods of using the same | CELGENE CORPORATION (US) | 2017-12-19 | — | — | US | disclosed |
| EP-3101017-A1 | 4'-O-SUBSTITUTED ISOINDOLINE DERIVATIVES AND COMPOSITIONS COMPRISING AND METHODS OF USING THE SAME | Celgene Corporation (US) | 2016-12-07 | — | — | EP | disclosed |
| EP-2142534-B1 | 4'-O-SUBSTITUTED ISOINDOLINE DERIVATIVES AND COMPOSITIONS COMPRISING AND METHODS OF USING THE SAME | CELGENE CORP (US) | 2016-08-10 | — | — | EP | disclosed |
| US-20160024048-A1 | 4'-O-SUBSTITUTED ISOINDOLINE DERIVATIVES AND COMPOSITIONS COMPRISING AND METHODS OF USING THE SAME | CELGENE CORPORATION | 2016-01-28 | — | — | US | disclosed |
| US-9181216-B2 | 4′-O-substituted isoindoline derivatives and compositions comprising and methods of using the same | CELGENE CORPORATION (US) | 2015-11-10 | — | — | US | disclosed |
| US-20140073669-A1 | 4'-O-SUBSTITUTED ISOINDOLINE DERIVATIVES AND COMPOSITIONS COMPRISING AND METHODS OF USING THE SAME | CELGENE CORPORATION | 2014-03-13 | — | — | US | disclosed |
| US-8614328-B2 | 4′-O-substituted isoindoline derivatives and compositions comprising and methods of using the same | CELGENE CORPORATION (US) | 2013-12-24 | — | — | US | disclosed |
| US-20120165536-A1 | 4'-O-SUBSTITUTED ISOINDOLINE DERIVATIVES AND COMPOSITIONS COMPRISING AND METHODS OF USING THE SAME | CELGENE CORPORATION | 2012-06-28 | — | — | US | disclosed |
| US-8153659-B2 | 4′-O-substituted isoindoline derivatives and compositions comprising and methods of using the same | CELGENE CORPORATION (US) | 2012-04-10 | — | — | US | disclosed |
| CN-101679380-A | 4' -O-substituted isoindoline derivatives and compositions comprising and methods of use | CELGENE CORP | 2010-03-24 | — | — | CN | disclosed |
| EP-2142534-A2 | 4'-O-SUBSTITUTED ISOINDOLINE DERIVATIVES AND COMPOSITIONS COMPRISING AND METHODS OF USING THE SAME | CELGENE CORPORATION (US) | 2010-01-13 | — | — | EP | disclosed |
| US-20090004209-A1 | 4'-O- substituted isoindoline derivatives and compositions comprising and methods of using the same | CELGENE CORPORATION | 2009-01-01 | — | — | US | disclosed |
| WO-2008115516-A2 | 4'-O-SUBSTITUTED ISOINDOLINE DERIVATIVES AND COMPOSITIONS COMPRISING AND METHODS OF USING THE SAME | CELGENE CORPORATION (US) | 2008-09-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140073669-A1 | 4'-O-SUBSTITUTED ISOINDOLINE DERIVATIVES AND COMPOSITIONS COMPRISING AND METHODS OF USING THE SAME | CYP3A4, CYP3A7, CYP4B1 | NR4A2 1545/4885MRGPRX4 1875/4885LMNA 2664/4885 |
| US-20160024048-A1 | 4'-O-SUBSTITUTED ISOINDOLINE DERIVATIVES AND COMPOSITIONS COMPRISING AND METHODS OF USING THE SAME | CYP3A4, CYP3A7, CYP4B1 | NR4A2 1545/4885MRGPRX4 1875/4885LMNA 2664/4885 |
| US-20090004209-A1 | 4'-O- substituted isoindoline derivatives and compositions comprising and methods of using the same | CYP3A4, CYP3A7, CYP4B1 | NR4A2 1545/4885MRGPRX4 1875/4885LMNA 2664/4885 |
| US-20120165536-A1 | 4'-O-SUBSTITUTED ISOINDOLINE DERIVATIVES AND COMPOSITIONS COMPRISING AND METHODS OF USING THE SAME | CYP3A4, CYP3A7, CYP4B1 | NR4A2 1545/4885MRGPRX4 1875/4885LMNA 2664/4885 |
| US-20180155316-A1 | 4'-O-SUBSTITUTED ISOINDOLINE DERIVATIVES AND COMPOSITIONS COMPRISING AND METHODS OF USING THE SAME | CYP3A4, CYP3A7, CYP4B1 | NR4A2 1545/4885MRGPRX4 1875/4885LMNA 2664/4885 |
| US-10385037-B2 | 4′-O-substituted isoindoline derivatives and compositions comprising and methods of using the same | CYP3A4, CYP3A7, CYP4B1 | NR4A2 1737/4885MRGPRX4 1970/4885LMNA 2541/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.